THTX's Business Model
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH1902, which is in Phase 1/Part A clinical trials for the treatment of triple negative breast cancer; and TH1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.
| Sector & Industry | Healthcare / Drug Manufacturers - Specialty & Generic |
| Website | https://www.theratech.com |
| CEO (Chief Executive Officer) | Paul Lévesque |
| Number of Employees | |
| IPO date | February 13, 2009 |
THTX Latest News
|
|
|
|
|
|
|
|
|
|
| Contact | |
|---|---|
| Country | CA |
| Address | 2015 Peel Street |
| City | Montreal |
| State | QC |
| Phone | 15143367800 |
| Zip Code | H3A 1T8 |
| Other Identifiers | |
| CIK | 0001512717 |
| ISIN | CA88338H7040 |
| CUSIP | 88338H704 |
| Open | 3.36 |
| Previous Close | 3.39 |
| Volume | 3.27 Mil. |
| Average Volume | 428.9 Thou. |
| Day’s Range | 3.36 – 3.39 |
| 52 Week Range | 1.12-3.4 |
| MA (50) | 3.2582 |
| MA (200) | 2.45228 |
| Market Cap | 155.9 Mil. |
| Shares Out. | 45.98 Mil. |
| Earnings Date | Oct 15, 2025 |
| Beta | |
| Last Dividend | |
| EPS | |
| PE | |
